UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000044655
Receipt number R000050723
Scientific Title Examination of the relationship between biomarkers in nasal discharge during initial wheezing and the onset of asthma in early childhood
Date of disclosure of the study information 2021/06/26
Last modified on 2021/06/25 13:36:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination of the relationship between biomarkers in nasal discharge during initial wheezing and the onset of asthma in early childhood

Acronym

Examination of the relationship between biomarkers in nasal discharge during initial wheezing and the onset of asthma in early childhood

Scientific Title

Examination of the relationship between biomarkers in nasal discharge during initial wheezing and the onset of asthma in early childhood

Scientific Title:Acronym

Examination of the relationship between biomarkers in nasal discharge during initial wheezing and the onset of asthma in early childhood

Region

Japan


Condition

Condition

Bronchial asthma

Classification by specialty

Pneumology Clinical immunology Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to clarify biomarkers that predict the onset of recurrent wheezing and asthma using blood and nasal discharge obtained under normal medical care for children who first wheeze in infancy.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Differences in nasal discharge biomarkers tested at the time of screening between children in the IgE-related asthma group, non-IgE-related asthma group, and non-asthma group.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit

2 years-old >

Gender

Male and Female

Key inclusion criteria

Infants under 2 years old who were hospitalized for lower respiratory tract infection and wheezing for the first time after birth
Children who have consented to participate in this study from their substitutes

Key exclusion criteria

Preterm infants (less than 37 weeks)
Children who required respiratory management during the newborn period, children with chronic lung disease
Children with a history of autoimmune diseases or metabolic diseases
Children who received treatment by steroids (inhalation, nasal drops, systemic administration) before sample collection (within 24 hours)
Other children who the researcher deems inappropriate for participating in this study

Target sample size

148


Research contact person

Name of lead principal investigator

1st name Fumitaka
Middle name
Last name Takayanagi

Organization

Dokkyo Medical University Hospital

Division name

Pediatrics

Zip code

321-0293

Address

880 Ozikiitakobayasshi Mibu Shimotsuga Tochigi

TEL

0282-86-1111

Email

fumi_fena@yahoo.co.jp


Public contact

Name of contact person

1st name Fumitaka
Middle name
Last name Takayanagi

Organization

Dokkyo Medical University Hospital

Division name

Pediatrics

Zip code

321-0293

Address

880 Ozikiitakobayasshi Mibu Shimotsuga Tochigi

TEL

0282-86-1111

Homepage URL


Email

fumi_fena@yahoo.co.jp


Sponsor or person

Institute

Dokkyo Medical University Hospital

Institute

Department

Personal name



Funding Source

Organization

Dokkyo Medical University Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Dokkyo Medical University Hospital

Address

880 Ozikiitakobayasshi Mibu Shimotsuga Tochigi

Tel

0282-86-1111

Email

fumi_fena@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 06 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2021 Year 06 Month 01 Day

Date of IRB

2021 Year 06 Month 01 Day

Anticipated trial start date

2021 Year 06 Month 01 Day

Last follow-up date

2029 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a multicenter prospective cohort study.
We enroll all patients who visited our hospital between approval by the Clinical Research Ethics Committee in 2021 and March 2023 who met the selection criteria.
We take a nasal discharge sample at admission and measure biomarkers.
After that, a questionnaire survey will be conducted every year for 5 years to evaluate the onset of asthma.
In addition, after 2 years and 5 years, asthma phenotypes will be classified according to the presence or absence of an increase in IgE, and it will be examined whether biomarkers differ for each phenotype.


Management information

Registered date

2021 Year 06 Month 25 Day

Last modified on

2021 Year 06 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000050723


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name